Details for New Drug Application (NDA): 022115
✉ Email this page to a colleague
NDA 022115 describes LAMICTAL XR, which is a drug marketed by Glaxosmithkline Llc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the LAMICTAL XR profile page.
The generic ingredient in LAMICTAL XR is lamotrigine. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.
The generic ingredient in LAMICTAL XR is lamotrigine. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.
Summary for 022115
| Tradename: | LAMICTAL XR |
| Applicant: | Glaxosmithkline Llc |
| Ingredient: | lamotrigine |
| Patents: | 1 |
Pharmacology for NDA: 022115
| Mechanism of Action | Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 022115
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115 | NDA | GlaxoSmithKline LLC | 0173-0754 | 0173-0754-00 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0754-00) |
| LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115 | NDA | GlaxoSmithKline LLC | 0173-0755 | 0173-0755-00 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0755-00) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 25MG | ||||
| Approval Date: | May 29, 2009 | TE: | AB | RLD: | Yes | ||||
| Patent: | 8,637,512 | Patent Expiration: | Jan 7, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 50MG | ||||
| Approval Date: | May 29, 2009 | TE: | AB | RLD: | Yes | ||||
| Patent: | 8,637,512 | Patent Expiration: | Jan 7, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 100MG | ||||
| Approval Date: | May 29, 2009 | TE: | AB | RLD: | Yes | ||||
| Patent: | 8,637,512 | Patent Expiration: | Jan 7, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Expired US Patents for NDA 022115
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-001 | May 29, 2009 | 9,144,547 | ⤷ Start Trial |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-004 | May 29, 2009 | 9,144,547 | ⤷ Start Trial |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-003 | May 29, 2009 | 9,144,547 | ⤷ Start Trial |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-006 | Jun 21, 2011 | 9,144,547 | ⤷ Start Trial |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-002 | May 29, 2009 | 9,144,547 | ⤷ Start Trial |
| Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-005 | Apr 14, 2010 | 9,144,547 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
